CN113906140B - A2/ny-eso-1特异性t细胞受体及其用途 - Google Patents

A2/ny-eso-1特异性t细胞受体及其用途 Download PDF

Info

Publication number
CN113906140B
CN113906140B CN202080031738.8A CN202080031738A CN113906140B CN 113906140 B CN113906140 B CN 113906140B CN 202080031738 A CN202080031738 A CN 202080031738A CN 113906140 B CN113906140 B CN 113906140B
Authority
CN
China
Prior art keywords
tcr
cancer
cell
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080031738.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113906140A (zh
Inventor
G·库克斯
M·艾维英
V·佐埃特
O·米切林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Cancer Research
Original Assignee
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Cancer Research filed Critical Ludwig Cancer Research
Publication of CN113906140A publication Critical patent/CN113906140A/zh
Application granted granted Critical
Publication of CN113906140B publication Critical patent/CN113906140B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
CN202080031738.8A 2019-03-18 2020-03-17 A2/ny-eso-1特异性t细胞受体及其用途 Active CN113906140B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819988P 2019-03-18 2019-03-18
US62/819,988 2019-03-18
PCT/IB2020/000140 WO2020188348A2 (en) 2019-03-18 2020-03-17 A2/ny-eso-1 specific t cell receptors and uses thereof

Publications (2)

Publication Number Publication Date
CN113906140A CN113906140A (zh) 2022-01-07
CN113906140B true CN113906140B (zh) 2025-01-28

Family

ID=70465122

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080031738.8A Active CN113906140B (zh) 2019-03-18 2020-03-17 A2/ny-eso-1特异性t细胞受体及其用途

Country Status (6)

Country Link
US (2) US12473346B2 (enExample)
EP (1) EP3941939A2 (enExample)
JP (1) JP7680032B2 (enExample)
CN (1) CN113906140B (enExample)
AU (1) AU2020243431B2 (enExample)
WO (1) WO2020188348A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN116420076A (zh) * 2020-09-27 2023-07-11 基因泰克公司 高通量多参数免疫细胞接合物筛选测定
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
US20240207319A1 (en) 2021-05-06 2024-06-27 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
EP4374872A1 (en) * 2022-11-22 2024-05-29 Koninklijke Philips N.V. Pde enhanced car-t cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107249606A (zh) * 2014-10-31 2017-10-13 宾夕法尼亚大学董事会 改变修饰的t细胞中的基因表达及其用途
CN108456247A (zh) * 2017-02-20 2018-08-28 上海恒润达生生物科技有限公司 靶向ny-eso-1的t细胞受体及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078334A1 (en) 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2008039818A2 (en) * 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008037943A1 (en) 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors
CA2700278A1 (en) 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Modified t cell receptors and related materials and methods
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
EP3377523A4 (en) * 2015-11-19 2019-06-19 The Regents of The University of California CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107249606A (zh) * 2014-10-31 2017-10-13 宾夕法尼亚大学董事会 改变修饰的t细胞中的基因表达及其用途
CN108456247A (zh) * 2017-02-20 2018-08-28 上海恒润达生生物科技有限公司 靶向ny-eso-1的t细胞受体及其用途

Also Published As

Publication number Publication date
JP2022525925A (ja) 2022-05-20
WO2020188348A2 (en) 2020-09-24
US20220152109A1 (en) 2022-05-19
US12473346B2 (en) 2025-11-18
US20260103503A1 (en) 2026-04-16
AU2020243431A1 (en) 2021-09-30
EP3941939A2 (en) 2022-01-26
CN113906140A (zh) 2022-01-07
WO2020188348A3 (en) 2020-12-17
JP7680032B2 (ja) 2025-05-20
CA3134102A1 (en) 2020-09-24
AU2020243431B2 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
JP7288405B2 (ja) ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体
EP3490585B1 (en) Immunomodulatory polypeptides and related compositions and methods
AU2020243431B2 (en) A2/NY-ESO-1 specific T cell receptors and uses thereof
US12187778B2 (en) Receptors providing targeted costimulation for adoptive cell therapy
JP2021072829A (ja) 治療用分子のｔ細胞送達のための組成物および方法
AU2015339106B2 (en) Compositions and methods of stimulating and expanding T cells
WO2017190100A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
KR20170068598A (ko) 입양 세포 치료에서 복용을 위한 방법 및 조성물
JP2019516350A (ja) キメラ抗原及びｔ細胞受容体、並びに使用方法
JP2017522893A (ja) Ｒｏｒ１特異的多重鎖キメラ抗原受容体
EP3774866A1 (en) Heterodimeric inactivatable chimeric antigen receptors
CA3165827A1 (en) Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
EP4182336A1 (en) Chimeric molecules providing targeted costimulation for adoptive cell therapy
TW202306997A (zh) 用於在過繼細胞療法中提供標靶共刺激之受體
JP2024509917A (ja) 腫瘍溶解性ウイルスによる直交性ｉｌ－２の送達を用いた、固形腫瘍におけるｔ細胞の選択的刺激方法
WO2023141530A2 (en) Receptors providing targeted costimulation for adoptive cell therapy
CA3134102C (en) A2/ny-eso-1 specific t cell receptors and uses thereof
JP2024502170A (ja) 癌のための改良された養子細胞移植療法
HK40058918A (en) A2/ny-eso-1 specific t cell receptors and uses thereof
JP2023536820A (ja) 二重ｃａｒ－ｔ細胞
HK40058918B (en) A2/ny-eso-1 specific t cell receptors and uses thereof
CN116685602A (zh) 用于同种异体细胞治疗的通用嵌合抗原受体表达免疫细胞
WO2024238938A1 (en) Modulation of the btla-hvem axis to enhance adoptive cell transfer immunotherapy
HK40100191A (en) Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy
HK40082776A (en) Anti-cd3 scfv and cytokine producing artificial antigen presenting cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058918

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant